• Abu Dhabi resident Abdulaziz Karmastaji gets vaccinated at Seha's cruise ship terminal facility in January
    Abu Dhabi resident Abdulaziz Karmastaji gets vaccinated at Seha's cruise ship terminal facility in January
  • Abu Dhabi resident Shaikha Al Dheiri waiting to get vaccinated.
    Abu Dhabi resident Shaikha Al Dheiri waiting to get vaccinated.
  • A healthcare worker smiles for the cameras.
    A healthcare worker smiles for the cameras.
  • Nearly 20,000 people are vaccinated daily at the centre.
    Nearly 20,000 people are vaccinated daily at the centre.
  • Mohamed Hawas Al Sadid, chief executive of Seha, said nearly 20,000 people are getting shots every day.
    Mohamed Hawas Al Sadid, chief executive of Seha, said nearly 20,000 people are getting shots every day.
  • People in the waiting room.
    People in the waiting room.
  • An Emirati waits for her turn to get the vaccine.
    An Emirati waits for her turn to get the vaccine.
  • A young Emirati at the vaccination centre at the Abu Dhabi Cruise Terminal area.
    A young Emirati at the vaccination centre at the Abu Dhabi Cruise Terminal area.
  • Aya, 24, and Jana, 18, after receiving the vaccine. The Sinopharm vaccine is available across the country without charge at dozens of hospitals, vaccination centres, majlis and clinics.
    Aya, 24, and Jana, 18, after receiving the vaccine. The Sinopharm vaccine is available across the country without charge at dozens of hospitals, vaccination centres, majlis and clinics.
  • The Covid-19 vaccination drive is the country's largest to date. The health authorities aim to inoculate half the population by the end of the first quarter.
    The Covid-19 vaccination drive is the country's largest to date. The health authorities aim to inoculate half the population by the end of the first quarter.
  • (L to R) - Emirati healthcare workers, Mouza Al Beshr, Khadija Al Nuaimi and Za,zam Al Naqbi at the Seha vaccination centre.
    (L to R) - Emirati healthcare workers, Mouza Al Beshr, Khadija Al Nuaimi and Za,zam Al Naqbi at the Seha vaccination centre.

Health

Sinopharm may offer immunity for up to six months but more research needed, top UAE official says

There has been a significant decrease in the rate of hospital admissions in Abu Dhabi since the country began a mass vaccination campaign

Gillian Duncan
Gillian Duncan

February 28, 2021

  • English
  • Arabic

Latest: Covid-19 booster shot: what's in it and how soon will you need it?

The Sinopharm vaccine is expected to offer people immunity against Covid-19 for four to six months, a top doctor involved in the UAE trial said.

Dr Nawal Al Kaabi, chairwoman of the National Covid-19 Clinical Management Committee, said Abu Dhabi's public health provider recorded a "significant decrease" in the rate of hospital admissions after the country began a mass vaccination campaign.

That was despite the second wave of the pandemic being worse than the first, she said.

There is a possibility that we will need a booster dose like any other inactivated vaccine

"The number of hospitalisations was much less and there were no critical care admissions seen among the vaccinated, 14 days post second dose," Dr Al Kaabi said on Friday at an online public health conference about the Covid-19 response.

“There was no mortality among the vaccinated. Even for those who got the infection, usually it is mild or asymptomatic.

“We also noticed that the duration of positivity is very short among the vaccinated.”

The duration of immunity offered by two doses of the vaccine is likely to last six months or less, although she said further data was needed to determine the exact period.

“What is the best estimate for how long the immunity will last? Now, it is around four to six months, however, we don’t have the final data,” said Dr Al Kaabi, a paediatric infectious diseases consultant and chief medical officer at Sheikh Khalifa Medical City.

Dr Nawal Al Kaabi, chairwoman of the National Covid-19 Clinical Management Committee, and Dr Walid Zaher, vaccine project leader at G42 Healthcare. Victor Besa / The National
Dr Nawal Al Kaabi, chairwoman of the National Covid-19 Clinical Management Committee, and Dr Walid Zaher, vaccine project leader at G42 Healthcare. Victor Besa / The National

“There is a possibility that we will need a booster dose like any other inactivated vaccine.”

The conference also received an update about the Sputnik V vaccine trial in the UAE, which should begin a small Phase 2 study. It will test a combination of Sputnik V and AstraZeneca shots.

“The advantage here is at the time when we have a shortage of one or the other vaccine, this provides a new way to use combinations of different vaccines,” said Dr Ahmed Al Hammadi, a consultant in infectious diseases at Tawam Hospital in Al Ain.

Sputnik V was approved for emergency use in the Emirates on January 21 after the country hosted a small-scale Phase 3 trial of the vaccine involving about 1,000 volunteers. The shot was produced by Gamaleya National Centre of Epidemiology and Microbiology.

Clinical trial data shows a 91.4 per cent efficacy for the Sputnik V vaccine 28 days after the first dose is administered and more than 95 per cent after 42 days.

Trials placed Sinopharm's efficacy at 79.34 per cent, but some experts said it could hold up better against variants than other vaccine types.

That is because it is derived from the whole virus and does not only target the spike protein, where the most concerning mutations have been found in the variants.

Most of the other vaccines currently in use all target the spike protein.

But medics are still examining how effective vaccines are against new strains, including the Sinopharm shot.

Sinopharm's Covid-19 vaccine production centre in Beijing - in pictures

  • Workers wait to enter the packaging area of Sinopharm's Covid-19 vaccine production centre in Beijing. Getty
    Workers wait to enter the packaging area of Sinopharm's Covid-19 vaccine production centre in Beijing. Getty
  • A worker in the packaging area of Sinopharm's vaccine production centre. Getty
    A worker in the packaging area of Sinopharm's vaccine production centre. Getty
  • Doses of the Covid-19 vaccine developed by Chinese pharmaceutical company Sinopharm. AFP
    Doses of the Covid-19 vaccine developed by Chinese pharmaceutical company Sinopharm. AFP
  • Doses of the Sinopharm vaccine during the packaging process. AFP
    Doses of the Sinopharm vaccine during the packaging process. AFP
  • Doses of the Sinopharm vaccine have been sent to countries around the world, including the UAE. AFP
    Doses of the Sinopharm vaccine have been sent to countries around the world, including the UAE. AFP
  • Doses of the Sinopharm vaccine pass along the production line. Reuters
    Doses of the Sinopharm vaccine pass along the production line. Reuters
  • Vaccine doses are prepared at the Sinopharm production centre in Beijing. Reuters
    Vaccine doses are prepared at the Sinopharm production centre in Beijing. Reuters
  • Doses pass through the packaging area of the Sinopharm vaccine production centre. Getty
    Doses pass through the packaging area of the Sinopharm vaccine production centre. Getty
  • Doses of the vaccine are prepared at the Sinopharm production centre. Reuters
    Doses of the vaccine are prepared at the Sinopharm production centre. Reuters
  • A staff member works next to the production line. Reuters
    A staff member works next to the production line. Reuters
  • A collection of Sinopharm vaccine doses on the production line. Reuters
    A collection of Sinopharm vaccine doses on the production line. Reuters
  • Workers in the packaging area of Sinopharm's vaccine production centre. Getty
    Workers in the packaging area of Sinopharm's vaccine production centre. Getty
  • Workers in the packaging area of Sinopharm's vaccine production centre. Getty
    Workers in the packaging area of Sinopharm's vaccine production centre. Getty
  • A box containing doses of the Sinopharm vaccine. AFP
    A box containing doses of the Sinopharm vaccine. AFP
  • A worker checks a box of vaccine doses. Reuters
    A worker checks a box of vaccine doses. Reuters
  • Boxes of Sinopharm's Covid-19 vaccine in the packaging area. The company says it is able to produce up to one billion doses this year. Getty
    Boxes of Sinopharm's Covid-19 vaccine in the packaging area. The company says it is able to produce up to one billion doses this year. Getty
  • A monitor shows real-time footage of the production line at Sinopharm's vaccine production centre. Reuters
    A monitor shows real-time footage of the production line at Sinopharm's vaccine production centre. Reuters
Ten tax points to be aware of in 2026

1. Domestic VAT refund amendments: request your refund within five years

If a business does not apply for the refund on time, they lose their credit.

2. E-invoicing in the UAE

Businesses should continue preparing for the implementation of e-invoicing in the UAE, with 2026 a preparation and transition period ahead of phased mandatory adoption. 

3. More tax audits

Tax authorities are increasingly using data already available across multiple filings to identify audit risks. 

4. More beneficial VAT and excise tax penalty regime

Tax disputes are expected to become more frequent and more structured, with clearer administrative objection and appeal processes. The UAE has adopted a new penalty regime for VAT and excise disputes, which now mirrors the penalty regime for corporate tax.

5. Greater emphasis on statutory audit

There is a greater need for the accuracy of financial statements. The International Financial Reporting Standards standards need to be strictly adhered to and, as a result, the quality of the audits will need to increase.

6. Further transfer pricing enforcement

Transfer pricing enforcement, which refers to the practice of establishing prices for internal transactions between related entities, is expected to broaden in scope. The UAE will shortly open the possibility to negotiate advance pricing agreements, or essentially rulings for transfer pricing purposes. 

7. Limited time periods for audits

Recent amendments also introduce a default five-year limitation period for tax audits and assessments, subject to specific statutory exceptions. While the standard audit and assessment period is five years, this may be extended to up to 15 years in cases involving fraud or tax evasion. 

8. Pillar 2 implementation 

Many multinational groups will begin to feel the practical effect of the Domestic Minimum Top-Up Tax (DMTT), the UAE's implementation of the OECD’s global minimum tax under Pillar 2. While the rules apply for financial years starting on or after January 1, 2025, it is 2026 that marks the transition to an operational phase.

9. Reduced compliance obligations for imported goods and services

Businesses that apply the reverse-charge mechanism for VAT purposes in the UAE may benefit from reduced compliance obligations. 

10. Substance and CbC reporting focus

Tax authorities are expected to continue strengthening the enforcement of economic substance and Country-by-Country (CbC) reporting frameworks. In the UAE, these regimes are increasingly being used as risk-assessment tools, providing tax authorities with a comprehensive view of multinational groups’ global footprints and enabling them to assess whether profits are aligned with real economic activity. 

Contributed by Thomas Vanhee and Hend Rashwan, Aurifer

Company name: Play:Date

Launched: March 2017 on UAE Mother’s Day

Founder: Shamim Kassibawi

Based: Dubai with operations in the UAE and US

Sector: Tech 

Size: 20 employees

Stage of funding: Seed

Investors: Three founders (two silent co-founders) and one venture capital fund

RESULT

Uruguay 3 Russia 0
Uruguay: Suárez (10'), Cheryshev (23' og), Cavani (90')
Russia: Smolnikov (Red card: 36')

Man of the match: Diego Godin (Uruguay)

UAECoronavirus